168 related articles for article (PubMed ID: 30379704)
1. New molecular targets in meningiomas: the present and the future.
Venur VA; Santagata S; Galanis E; Brastianos PK
Curr Opin Neurol; 2018 Dec; 31(6):740-746. PubMed ID: 30379704
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?
Pellerino A; Bruno F; Palmiero R; Pronello E; Bertero L; Soffietti R; Rudà R
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565385
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
4. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
6. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
7. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
8. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
[TBL] [Abstract][Full Text] [Related]
9. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
[TBL] [Abstract][Full Text] [Related]
10. Medical management of meningiomas.
Chukwueke UN; Wen PY
Handb Clin Neurol; 2020; 170():291-302. PubMed ID: 32586501
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
Peyre M; Kalamarides M
Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
[TBL] [Abstract][Full Text] [Related]
12. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Shankar GM; Abedalthagafi M; Vaubel RA; Merrill PH; Nayyar N; Gill CM; Brewster R; Bi WL; Agarwalla PK; Thorner AR; Reardon DA; Al-Mefty O; Wen PY; Alexander BM; van Hummelen P; Batchelor TT; Ligon KL; Ligon AH; Meyerson M; Dunn IF; Beroukhim R; Louis DN; Perry A; Carter SL; Giannini C; Curry WT; Cahill DP; Barker FG; Brastianos PK; Santagata S
Neuro Oncol; 2017 Apr; 19(4):535-545. PubMed ID: 28170043
[TBL] [Abstract][Full Text] [Related]
13. Innovative Therapeutic Strategies in the Treatment of Meningioma.
Caruso G; Elbabaa SK; Gonzalez-Lopez P; Barresi V; Passalacqua M; Caffo M
Anticancer Res; 2015 Dec; 35(12):6391-400. PubMed ID: 26637848
[TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape of Meningiomas.
Wang JZ; Nassiri F; Mawrin C; Zadeh G
Adv Exp Med Biol; 2023; 1416():137-158. PubMed ID: 37432625
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Karimi S; Mansouri S; Nassiri F; Bunda S; Singh O; Brastianos PK; Dunn IF; Zadeh G
J Neurooncol; 2021 Feb; 151(3):443-449. PubMed ID: 33611710
[TBL] [Abstract][Full Text] [Related]
16. Meningioma genomics: a therapeutic challenge for clinicians.
Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
[TBL] [Abstract][Full Text] [Related]
17. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study.
Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA
J Neurosurg; 2024 Jan; ():1-7. PubMed ID: 38277657
[TBL] [Abstract][Full Text] [Related]
18. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
19. BAP1 mutations in high-grade meningioma: implications for patient care.
Shankar GM; Santagata S
Neuro Oncol; 2017 Oct; 19(11):1447-1456. PubMed ID: 28482042
[TBL] [Abstract][Full Text] [Related]
20. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.
Maggio I; Franceschi E; Di Nunno V; Gatto L; Tosoni A; Angelini D; Bartolini S; Lodi R; Brandes AA
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]